Report #2885090

Received Feb 10, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 87 yrs
State: TX
Recovered: Unknown
Vaccinated: Dec 15, 2025
Onset: Dec 15, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	X5FN4	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

wants the patient to receive a third dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a elderly female patient who received Herpes zoster (Shingrix) (batch number X5FN4, expiry date 17-JUN-2027) for prophylaxis. Previously administered products included Shingrix (received first dose on 14-NOV-2020 with batch number 3R774 and having expiry date 03-AUG-2022). On 15-DEC-2025, the patient received the 2nd dose of Shingrix. On 15-DEC-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: wants the patient to receive a third dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 05-FEB-2026 The patient reported that the prescribing physician had wanted them to receive a third dose. The batch number was provided and a request for this information has been made.